Add like
Add dislike
Add to saved papers

The expression and effects the CABYR-c transcript of CABYR gene in hepatocellular carcinoma.

Bulletin du Cancer 2012 March 2
BACKGROUND AND AIM: CABYR, a calcium-binding tyrosine phosphorylation regulated fibrous sheath protein, was initially reported to be testis-specific and subsequently shown to be present in brain tumors, pancreas cancer and lung cancer. This study aimed to investigate the expression and effects of the CABYR-c transcript of CABYR gene in hepatocellular carcinoma.

METHODS: mRNA and protein expression of CABYR-c was examined in 20 paired hepatocellular carcinoma tissues and adjacent non-cancerous tissues by real-time quantitative RT-polymerase chain reaction (PCR) and western blot analysis respectively. HepG2 cells were treated with the antisense oligodeoxynucleotides targeting CABYR-c mRNA (CABYR-c antisense oligonucleotides [AS ODNs]) for indicated times, the AS ODNs inhibition effect was evaluated by measuring the CABYR-c mRNA expression level of HepG2 cells after treatment using real-time quantitative RT-PCR, then cell proliferation was studied using MTT assay, and cell cycle distribution and apoptosis were detected by flow cytometry as well.

RESULTS: CABYR-c mRNA levels in hepatocellular carcinoma tissues were significantly higher than that in the paired adjacent non-cancerous tissues (27.5 ± 1.2 versus 2.5 ± 0. 9, P < 0.01). CABYR-c protein expression level in hepatocellular carcinoma tissues was also significantly higher than that in adjacent non-cancerous tissues. CABYR-c mRNA expression in HepG2 cells was most effective down-regulated after treatment of 600 nM CABYR-c AS ODNs for 48 h, which was selected for subsequent experiments. Incubation with 600 nM CABYR-c AS ODNs inhibited the cell growth of HepG2 cells in a dose- and time-dependent manner. The maximum inhibitory effect achieved at 600 nM after 72 h treatment (30.92 ± 3.25%, P < 0.01). HepG2 cells treated 600 nM CABYR-c AS ODNs for 48 h exhibited an increasing proportion of cells in G0/G1 phase (P < 0.05) and a decreasing proportion of cells in S phase (P < 0.05), compared with untreated controls. No obvious differences were observed in G2/M phase. The fraction of apoptotic HepG2 cells in CABYR-c AS ODNs treated group was less than that of untreated control group (P < 0.05).

CONCLUSION: CABYR-c is highly expressed in hepatocellular carcinoma tissues and may play an oncogenic role in heptocarcinogenesis as well as its progression.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app